13th Alzheimer’s & Parkinson’s Drug Development Summit

In 2025, the spotlight is on neurodegenerative drug development, driven by the triumph of Lecanemab and Donanemab, coupled with rapid advancements to enable presymptomatic diagnosis, reinvigorating the space with new targets, modalities, and technologies. Meanwhile significant advancements to target the likes of α-synuclein, NLRP3 and GBA suggest only a matter of time until a disease-modifying therapy emerges on the scene for Parkinson’s too.

Capitalizing on a new era of revitalized hope and momentum, the 13^th Alzheimer’s & Parkinson’s Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical, regulatory, and commercial development.

Join industry’s premier gathering of 150+ Alzheimer’s and Parkinson’s experts, with pioneering insights from the likes of Eisai, Eli Lilly, Biogen, and Roche, as they address their most pressing challenges in a collaborative atmosphere to spearhead the next wave of more truly transformative neurodegenerative therapeutics.

https://www.canva.com/design/DAGU4QFJQUY/jZuszxCPdmkOcHcS0bN3ig/watch